Atelvia (Risedronate Sodium) Patent Expiration, LOE Window & CMS Spending

Atelvia (Risedronate Sodium) by AbbVie: FDA Orange Book LOE 2028-01-09, 1 AB generics, $172K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN022560 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2028-01-09
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$172K
2024 Medicare Part D Spend$172K
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.